127 related articles for article (PubMed ID: 2245491)
1. Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.
Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher RI
Cancer Chemother Pharmacol; 1990; 27(1):33-40. PubMed ID: 2245491
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience.
Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher SG; Fisher RI
Semin Oncol; 1992 Jun; 19(3 Suppl 9):102-9. PubMed ID: 1641650
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
4. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
[TBL] [Abstract][Full Text] [Related]
5. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma.
Schilsky RL; Williams SF; Ultmann JE; Watson S
J Clin Oncol; 1987 Mar; 5(3):419-25. PubMed ID: 3819808
[TBL] [Abstract][Full Text] [Related]
6. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).
Swinnen LJ; Rankin C; Carraway H; Albain KS; Townsend JJ; Budd GT; Kish JA; Rivkin SE; Blumenthal DT
J Neurooncol; 2008 Feb; 86(3):353-8. PubMed ID: 18175205
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy.
Atkins JN; Muss HB; Capizzi RL; Cooper MR; Craig J; Cruz JM; Jackson DV; Powell B; Richards F; Spurr CL
Cancer Treat Rep; 1985; 69(7-8):897-9. PubMed ID: 4040427
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of cytarabine and hydroxyurea.
Pfeifle CE; Howell SB
Cancer Treat Rep; 1983 Dec; 67(12):1127-9. PubMed ID: 6652629
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.
Schilsky RL; Muscato JJ; Muscato MS; Perry MC
Cancer Treat Rep; 1984 Sep; 68(9):1097-102. PubMed ID: 6541094
[TBL] [Abstract][Full Text] [Related]
12. ViVACCy--a drug schedule based on G2 blockade and prolonged infusion of multiple tubulin-binding agents. A pilot study.
Shackney SE; Pugh RP; Zidar BL; Raju RN; Simon SR; Mazur RN; Mucenski JW
Cancer; 1990 Aug; 66(3):411-7. PubMed ID: 2194639
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.
Tetef M; Leong L; Ahn C; Akman S; Chow W; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Doroshow JH
Cancer Invest; 1999; 17(2):114-7. PubMed ID: 10071595
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer.
Cantwell BM; Veale D; Rivett C; Ghani S; Harris AL
Cancer Chemother Pharmacol; 1989; 23(4):252-4. PubMed ID: 2538251
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
[TBL] [Abstract][Full Text] [Related]
20. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
